CYP3A4 and pneumocystosis: In the second VEN + HMA study, prophylaxis was optional; in the VEN + HMA group (n = 40), strong or moderate CYP3A4 inhibitors were given in 22.5% of patients, and PJP prophylaxis was given in 12.5% of patients.